Current Opinion in Ophthalmology, Journal Year: 2022, Volume and Issue: unknown
Published: Nov. 22, 2022
Purpose of review Currently, glaucoma treatment drugs are facing problems such as low bioavailability, poor patient compliance, discontinuous administration affecting the efficacy intraocular pressure (IOP) lowering and chronic damage to eye caused by side effects drugs. In order solve these better meet clinical needs, various new dosage forms have been developed applied in setting. Recent findings A number nano formulations extended-release gels successive animal trials, some tear plugs, implants contact lenses it is believed that more carrier materials improve bioavailability being developed. Summary Novel delivery systems for antiglaucoma offer patients therapeutic options, ongoing or completed studies providing clear directions subsequent research applications.
Language: Английский